Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Permian Resources Corporation Class A Common Stock (PR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Permian Resources Corporation Class A Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Permian Resources Corporation Class A Common Stock trades at $24.13 (market cap $20.32B). The key difference: Permian Resources Corporation Class A Common Stock is far larger — about 2.3× Kymera Therapeutics Inc. Common Stock's market cap, and Permian Resources Corporation Class A Common Stock pays a 2.6% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Permian Resources Corporation Class A Common Stock for 5 Days on average.
| KYMR | PR | |
|---|---|---|
Market Cap | $8.87B | $20.32B |
Volume | 779,107 | 10,979,775 |
Sector | Health | Energy |
52-Week High | $127.31 | $24.49 |
52-Week Low | $55.80 | $12.09 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $8.26B | $23.32B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Permian Resources (PR) trades at $24.26, up 3.68% on the day and near its 52-week high, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $5.07B revenue, 21.52% net income margin, and attractive valuation metrics including a P/E of 15.65 and EV/EBITDA of 5.83. Recent earnings show mixed results with Q2 2026 beating expectations by 59% while Q1 2026 missed estimates.
The outlook remains positive with 90% analyst buy ratings and $27.00 consensus price target representing 11% upside. Key opportunities include disciplined acquisition strategy and raised 2026 guidance, while risks involve oil price volatility and execution of capital spending plans. The stock offers growth potential but requires monitoring of quarterly execution consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Permian Resources Corporation Class A Common Stock
Permian Resources explores for and produces oil and natural gas in the Permian Basin. Its operations are concentrated in the Delaware Basin of West Texas and New Mexico.
Read more on PR →
